MX2016010504A - Metodos para el tratamiento de pacientes con hipercolesterolemia que no esta controlada adecuadamente por una terapia con estatinas de dosis moderada referencia cruzada a solicitudes relacionas. - Google Patents
Metodos para el tratamiento de pacientes con hipercolesterolemia que no esta controlada adecuadamente por una terapia con estatinas de dosis moderada referencia cruzada a solicitudes relacionas.Info
- Publication number
- MX2016010504A MX2016010504A MX2016010504A MX2016010504A MX2016010504A MX 2016010504 A MX2016010504 A MX 2016010504A MX 2016010504 A MX2016010504 A MX 2016010504A MX 2016010504 A MX2016010504 A MX 2016010504A MX 2016010504 A MX2016010504 A MX 2016010504A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- hypercholesterolemia
- moderate
- treating patients
- statin therapy
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 208000035150 Hypercholesterolemia Diseases 0.000 title abstract 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 229940122392 PCSK9 inhibitor Drugs 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461939857P | 2014-02-14 | 2014-02-14 | |
| US201462000162P | 2014-05-19 | 2014-05-19 | |
| US201462025094P | 2014-07-16 | 2014-07-16 | |
| US201462052227P | 2014-09-18 | 2014-09-18 | |
| EP14306729 | 2014-10-29 | ||
| PCT/US2015/015633 WO2015123423A2 (en) | 2014-02-14 | 2015-02-12 | Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016010504A true MX2016010504A (es) | 2016-12-09 |
Family
ID=51870958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016010504A MX2016010504A (es) | 2014-02-14 | 2015-02-12 | Metodos para el tratamiento de pacientes con hipercolesterolemia que no esta controlada adecuadamente por una terapia con estatinas de dosis moderada referencia cruzada a solicitudes relacionas. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20150231236A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3104879A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2017506626A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20160115939A (cg-RX-API-DMAC7.html) |
| CN (1) | CN106029096A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015217118A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2939507A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201691320A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2016010504A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015123423A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| AR084938A1 (es) | 2011-01-28 | 2013-07-10 | Sanofi Sa | Anticuerpos humanos contra la proproteina convertasa subtilisina/kexina tipo 9 (anti pcsk9) para usar en metodos para tratar grupos de pacientes |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| ES2773111T3 (es) | 2011-09-16 | 2020-07-09 | Regeneron Pharma | Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a) |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| US20140257473A1 (en) * | 2012-10-22 | 2014-09-11 | Nalini Marie Rajamannan | Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis |
| US10058630B2 (en) | 2012-10-22 | 2018-08-28 | Concievalve, Llc | Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| TW201534324A (zh) | 2013-06-07 | 2015-09-16 | Sanofi Sa | 藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法 |
| CN106062003A (zh) | 2013-11-12 | 2016-10-26 | 赛诺菲生物技术公司 | 用于与pcsk9抑制剂一起使用的给药方案 |
| US20230374155A1 (en) * | 2014-05-15 | 2023-11-23 | Rani Therapeutics, Llc | Pcsk9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US10689460B2 (en) * | 2014-05-15 | 2020-06-23 | Incube Labs, Llc | PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| CA3198322A1 (en) | 2014-05-15 | 2015-11-19 | Rani Therapeutics, Llc | Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins |
| AU2015289874A1 (en) * | 2014-07-14 | 2017-02-02 | Amgen Inc. | Crystalline antibody formulations |
| KR20240017117A (ko) | 2014-07-16 | 2024-02-06 | 사노피 바이오테크놀로지 | 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법 |
| EA201890519A1 (ru) | 2015-08-18 | 2018-07-31 | Ридженерон Фармасьютикалз, Инк. | Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов |
| CN108401419A (zh) * | 2015-09-08 | 2018-08-14 | 因库博实验室有限责任公司 | 使用可吞服药物递送装置递送到肠道内腔中的pcsk9抗体制剂 |
| US20170332139A1 (en) | 2016-05-10 | 2017-11-16 | Rovi Guides, Inc. | System and method for delivering missed portions of media assets to interested viewers |
| EP3474780A4 (en) * | 2016-06-27 | 2020-02-26 | Concievalve LLC | METHODS OF INHIBITING STENOSIS, OBSTRUCTING OR CALCIFYING A CARDIAC VALVE WITH STENT OR BIOPROSTHESIS |
| BR112019020148A2 (pt) | 2017-04-13 | 2020-05-05 | Cadila Healthcare Ltd | peptídeo |
| GB201720162D0 (en) | 2017-12-04 | 2018-01-17 | Univ Oxford Innovation Ltd | Method |
| US11248001B2 (en) | 2019-01-18 | 2022-02-15 | Astrazeneca Ab | PCSK9 inhibitors and methods of use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| AR084938A1 (es) * | 2011-01-28 | 2013-07-10 | Sanofi Sa | Anticuerpos humanos contra la proproteina convertasa subtilisina/kexina tipo 9 (anti pcsk9) para usar en metodos para tratar grupos de pacientes |
| ES2773111T3 (es) * | 2011-09-16 | 2020-07-09 | Regeneron Pharma | Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a) |
| US9255154B2 (en) * | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| JP2015517579A (ja) * | 2012-05-25 | 2015-06-22 | カタバシス ファーマシューティカルズ，インコーポレイテッド | プロタンパク質転換酵素スブチリシン／ケキシン９型（ｐｃｓｋ９）を低下させる方法 |
-
2015
- 2015-02-12 WO PCT/US2015/015633 patent/WO2015123423A2/en not_active Ceased
- 2015-02-12 CN CN201580008411.8A patent/CN106029096A/zh active Pending
- 2015-02-12 KR KR1020167022444A patent/KR20160115939A/ko not_active Ceased
- 2015-02-12 MX MX2016010504A patent/MX2016010504A/es unknown
- 2015-02-12 AU AU2015217118A patent/AU2015217118A1/en not_active Abandoned
- 2015-02-12 EP EP15710616.2A patent/EP3104879A2/en not_active Withdrawn
- 2015-02-12 JP JP2016550471A patent/JP2017506626A/ja active Pending
- 2015-02-12 US US14/621,000 patent/US20150231236A1/en not_active Abandoned
- 2015-02-12 CA CA2939507A patent/CA2939507A1/en not_active Abandoned
- 2015-02-12 EA EA201691320A patent/EA201691320A1/ru unknown
-
2018
- 2018-06-28 US US16/022,255 patent/US20180296672A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015123423A3 (en) | 2015-10-08 |
| JP2017506626A (ja) | 2017-03-09 |
| EA201691320A1 (ru) | 2016-11-30 |
| CA2939507A1 (en) | 2015-08-20 |
| US20150231236A1 (en) | 2015-08-20 |
| AU2015217118A1 (en) | 2016-08-18 |
| WO2015123423A2 (en) | 2015-08-20 |
| EP3104879A2 (en) | 2016-12-21 |
| KR20160115939A (ko) | 2016-10-06 |
| US20180296672A1 (en) | 2018-10-18 |
| CN106029096A (zh) | 2016-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016010504A (es) | Metodos para el tratamiento de pacientes con hipercolesterolemia que no esta controlada adecuadamente por una terapia con estatinas de dosis moderada referencia cruzada a solicitudes relacionas. | |
| MX2020004023A (es) | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. | |
| MX2021000898A (es) | Inhibidores de pcsk9 para usarse en el tratamiento de pacientes con hipercolesterolemia familiar heterocigota (hfhe). | |
| MX2021000289A (es) | Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia. | |
| PH12018500097A1 (en) | Combination of pd-1 antagonist with an egfr inhibitor | |
| EA201591591A1 (ru) | Соединения карбазола, применяемые в качестве ингибиторов бромодомена | |
| EA201790932A1 (ru) | Дозировка и введение нефукозилированных анти-cd40 антител | |
| PH12016500582B1 (en) | Heterocyclic compounds and uses thereof | |
| EA201691845A1 (ru) | Фармацевтические композиции терапевтически активных соединений | |
| MX383866B (es) | Inhibidores de ezh2 para tratar linfomas. | |
| MX2016014306A (es) | Marcadores para terapia con lipoproteinas de alta densidad (hdl). | |
| MX2015012882A (es) | Compuestos y composiciones terapeuticos. | |
| PH12016502355B1 (en) | Pharmaceutical composition | |
| EA201791516A1 (ru) | Способы комбинированного лечения злокачественных опухолей | |
| EA201691481A1 (ru) | ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ | |
| EA201791736A1 (ru) | Комбинированная терапия для лечения рака | |
| MX373851B (es) | Métodos de administración de tratamiento con pirfenidona. | |
| EA201691844A1 (ru) | Фармацевтические композиции терапевтически активных соединений | |
| MX385283B (es) | Tratamiento de cáncer usando 2-desoxi-2-fluoro-l-fucosa en combinación con un inhibidor del punto de control. | |
| EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
| TW201613578A (en) | Pharmaceutical combinations | |
| PH12016502352A1 (en) | Pharmaceutical composition | |
| EA202090266A1 (ru) | Ингибиторы mpo для применения в медицине | |
| UA116499C2 (uk) | (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині | |
| MX369090B (es) | Sultiame para el tratamiento de apnea del sueño. |